Return of individual genomic research results within the PRAEGNANT multicenter registry study.

Publikation

Return of individual genomic research results within the PRAEGNANT multicenter registry study.

Wissenschaftlicher Artikel/Review - 21.11.2022

Huebner Hanna, Ruebner Matthias, Kurbacher Christian, Hadji Peyman, Hartkopf Andreas D, Lux Michael P, Huober Jens, Uhrig Sabrina, Taran Florin-Andrei, Overkamp Friedrich, Tesch Hans, Häberle Lothar, Luftner Diana, Wallwiener Markus, Müller Volkmar, Beckmann Matthias W, Hein Alexander, Belleville Erik, Untch Michael, Janni Wolfgang, Fehm Tanja N, Kolberg Hans-Christian, Wallwiener Diethelm, Brucker Sara Y, Schneeweiss Andreas, Ettl Johannes, Fasching Peter A, Michel Laura L

Zitation

Huebner H, Ruebner M, Kurbacher C, Hadji P, Hartkopf A, Lux M, Huober J, Uhrig S, Taran F, Overkamp F, Tesch H, Häberle L, Luftner D, Wallwiener M, Müller V, Beckmann M, Hein A, Belleville E, Untch M, Janni W, Fehm T, Kolberg H, Wallwiener D, Brucker S, Schneeweiss A, Ettl J, Fasching P, Michel L. Return of individual genomic research results within the PRAEGNANT multicenter registry study. Breast Cancer Res Treat 2022

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Breast Cancer Res Treat 2022

Veröffentlichungsdatum

21.11.2022

eISSN (Online)

1573-7217

Kurzbeschreibung/Zielsetzung

The PRAEGNANT study is a registry study for metastatic breast cancer patients, focusing on biomarker detection. Recently, within this study, genetic alterations in 37 breast cancer predisposition genes were analyzed and genetic findings were detected for 396 participants. The aim of this project was to return genetic results to the physicians and to analyze actions taken (e.g., disclosure of results to patients, validation of results, clinical impact, and impact on the patient's quality of life) using a questionnaire.